Blogs about: Xl 228
Featured Blog
Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I
Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor XL228 to show signs of Clinical Benefit inpatients with advanced malignancies… more →
Kinase News
Exelixis IGF-1R/Src inhibitor XL228 effective in Phase I
wrote 1 year ago: Phase I data presented at the EORTC-NCI-AACR Symposium show Exelixis’ IGF-1R/Src inhibitor XL … more →
Exelixis Bcr-Abl inhibitor shows efficacy in CML
wrote 1 year ago: Phase I data presented at the European Hematology Association (EHA) meeting shows Exelixis’ Bc … more →
